at Oxford Business Park, supporting expanded strategy Oxford, UK - 9 April 2021 - Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch® 3D genomics platform, has signed a lease agreement for new laboratory and office space at Oxford Business Park , to significantly expand its UK facilities. The 24,000 sq ft premises will house the Company s growing UK infrastructure, as it continues the execution of its expanded strategic focus , announced in December 2020. The new lease follows the recent launches of OBD s EpiSwitch The larger space will allow OBD to operate independent processing lines for commercial test development and product support, biomarker discovery contracts, clinical trial support and internal R&D projects. The new facility will also provide custom-designed space for product manufacturing, sa